3.17
price down icon2.46%   -0.08
after-market Dopo l'orario di chiusura: 3.21 0.04 +1.26%
loading
Precedente Chiudi:
$3.25
Aprire:
$3.25
Volume 24 ore:
1.53M
Relative Volume:
1.21
Capitalizzazione di mercato:
$343.45M
Reddito:
$27.08M
Utile/perdita netta:
$-37.00M
Rapporto P/E:
-6.0962
EPS:
-0.52
Flusso di cassa netto:
$-18.46M
1 W Prestazione:
-3.35%
1M Prestazione:
+25.79%
6M Prestazione:
+115.65%
1 anno Prestazione:
-1.55%
Intervallo 1D:
Value
$3.16
$3.385
Intervallo di 1 settimana:
Value
$3.12
$3.475
Portata 52W:
Value
$1.05
$3.475

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name
Nome
Aclaris Therapeutics Inc
Name
Telefono
484-324-7933
Name
Indirizzo
701 LEE ROAD, WAYNE, PA
Name
Dipendente
64
Name
Cinguettio
@aclaristx
Name
Prossima data di guadagno
2025-02-24
Name
Ultimi documenti SEC
Name
ACRS's Discussions on Twitter

Confronta ACRS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ACRS
Aclaris Therapeutics Inc
3.17 352.12M 27.08M -37.00M -18.46M -0.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.71 114.69B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
752.62 77.91B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
850.95 54.05B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
391.50 52.52B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
196.92 42.02B 447.02M -1.18B -906.14M -6.1812

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-10 Ripresa Piper Sandler Overweight
2025-05-28 Iniziato Wedbush Outperform
2025-03-18 Ripresa Cantor Fitzgerald Overweight
2024-12-23 Aggiornamento H.C. Wainwright Neutral → Buy
2024-11-20 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2024-11-19 Aggiornamento BTIG Research Neutral → Buy
2024-11-19 Aggiornamento Jefferies Hold → Buy
2024-11-19 Aggiornamento Leerink Partners Market Perform → Outperform
2024-11-18 Aggiornamento Piper Sandler Neutral → Overweight
2024-01-22 Downgrade H.C. Wainwright Buy → Neutral
2023-11-13 Downgrade William Blair Outperform → Mkt Perform
2023-10-03 Iniziato Evercore ISI Outperform
2022-12-14 Iniziato Stifel Buy
2022-12-01 Iniziato Goldman Buy
2022-10-06 Iniziato BTIG Research Buy
2021-07-23 Ripresa Jefferies Buy
2021-06-15 Iniziato Piper Sandler Overweight
2021-04-21 Iniziato H.C. Wainwright Buy
2019-10-22 Aggiornamento SVB Leerink Mkt Perform → Outperform
2019-09-06 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2019-06-27 Downgrade SVB Leerink Outperform → Mkt Perform
2019-05-06 Iniziato SVB Leerink Outperform
2018-03-28 Ripresa Leerink Partners Outperform
2018-02-09 Iniziato Guggenheim Buy
2017-06-16 Iniziato Cantor Fitzgerald Overweight
2016-11-29 Iniziato Leerink Partners Outperform
2016-09-30 Iniziato JMP Securities Mkt Outperform
2016-06-10 Iniziato Guggenheim Buy
2015-11-02 Iniziato Citigroup Buy
2015-11-02 Iniziato Jefferies Buy
Mostra tutto

Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie

pulisher
Dec 08, 2025

Aclaris Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis

Dec 08, 2025
pulisher
Dec 08, 2025

It is Poised to be a Bull Market for Aclaris Therapeutics Inc (ACRS) - setenews.com

Dec 08, 2025
pulisher
Dec 05, 2025

Can Aclaris Therapeutics Inc. stock deliver sustainable ROE2025 Key Highlights & Consistent Return Investment Signals - Newser

Dec 05, 2025
pulisher
Dec 04, 2025

Why Aclaris Therapeutics Inc. (8AT) stock is a must watch tickerTrade Risk Assessment & Weekly Stock Performance Updates - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 04, 2025
pulisher
Dec 04, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Dec 04, 2025
pulisher
Dec 04, 2025

How Aclaris Therapeutics Inc. (8AT) stock correlates with oil markets2025 Growth vs Value & Technical Pattern Recognition Alerts - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Can Comfort Intech Limited Maintain Profitability in a Rising Rate EnvironmentCandlestick Trading Patterns & Free Dynamic Profit Opportunities - earlytimes.in

Dec 04, 2025
pulisher
Dec 03, 2025

Is Aclaris Therapeutics Inc. stock attractive for income investors2025 Big Picture & Safe Capital Growth Trade Ideas - Newser

Dec 03, 2025
pulisher
Dec 02, 2025

Aclaris Therapeutics (ACRS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 02, 2025
pulisher
Dec 02, 2025

Aclaris Therapeutics engages investors at Piper Sandler Conference - Traders Union

Dec 02, 2025
pulisher
Dec 01, 2025

Aclaris Therapeutics Inc (ACRS) is looking forward to a strong quarter - Setenews

Dec 01, 2025
pulisher
Nov 30, 2025

Why Aclaris Therapeutics Inc. stock could rally in 2025Trade Analysis Report & Long-Term Capital Growth Ideas - BỘ NỘI VỤ

Nov 30, 2025
pulisher
Nov 27, 2025

Can Aclaris Therapeutics Inc. stock beat analyst upgrades - moha.gov.vn

Nov 27, 2025
pulisher
Nov 27, 2025

Check out Aclaris Therapeutics's stock price (ACRS) in real time - CNBC

Nov 27, 2025
pulisher
Nov 26, 2025

Aclaris Therapeutics, Inc.Common Stock (NQ: ACRS - Markets Financial Content

Nov 26, 2025
pulisher
Nov 25, 2025

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times

Nov 25, 2025
pulisher
Nov 24, 2025

Top investors say Aclaris Therapeutics Inc (ACRS) ticks everything they need - setenews.com

Nov 24, 2025
pulisher
Nov 21, 2025

Why Aclaris Therapeutics Inc. (8AT) stock attracts HNW investors - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

Is Aclaris Therapeutics Inc. (8AT) stock bottoming after sell offMarket Risk Analysis & Growth Focused Entry Reports - newser.com

Nov 21, 2025
pulisher
Nov 20, 2025

Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MSN

Nov 20, 2025
pulisher
Nov 20, 2025

Discovering Aclaris Therapeutics And Two Other Noteworthy Penny Stocks - Yahoo Finance

Nov 20, 2025
pulisher
Nov 20, 2025

How Aclaris Therapeutics Inc. stock benefits from tech adoptionNew Guidance & Smart Money Movement Alerts - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

What hedge fund moves indicate for Aclaris Therapeutics Inc. (8AT) stockTrade Signal Summary & Daily Momentum Trading Reports - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

Is Aclaris Therapeutics Inc. stock a contrarian buyPortfolio Performance Report & Entry Point Confirmation Signals - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Will Aclaris Therapeutics Inc. (8AT) stock benefit from mergers2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Is Aclaris Therapeutics Inc. (8AT) stock a buy for dividend portfoliosLayoff News & Fast Momentum Entry Tips - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

How cyclical is Aclaris Therapeutics Inc. (8AT) stock compared to rivalsPortfolio Value Report & Daily Technical Stock Forecast Reports - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Can Aclaris Therapeutics Inc. stock deliver strong Q4 earnings2025 Market Sentiment & Weekly Watchlist for Hot Stocks - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

What high frequency data says about Aclaris Therapeutics Inc.2025 Market Outlook & Safe Entry Momentum Stock Tips - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Rheumatoid Arthritis Market to Grow Significantly from ~20 Billion Over the Next Decade by 2034, DelveInsight Observes | R-Pharm, Taisho Pharmaceuticals, GSK, Aclaris, BMS, Eli Lilly, Taiho - Barchart.com

Nov 19, 2025
pulisher
Nov 17, 2025

Aclaris Therapeutics at Jefferies Conference: Strategic Expansion in Biopharma By Investing.com - Investing.com Canada

Nov 17, 2025
pulisher
Nov 17, 2025

Will Aclaris Therapeutics Inc. stock deliver shareholder value2025 Dividend Review & Weekly Setup with ROI Potential - newser.com

Nov 17, 2025

Aclaris Therapeutics Inc Azioni (ACRS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$38.53
price up icon 0.36%
$98.64
price up icon 3.39%
$31.57
price up icon 0.83%
$93.81
price down icon 1.05%
biotechnology ONC
$310.67
price down icon 2.63%
$196.92
price down icon 0.05%
Capitalizzazione:     |  Volume (24 ore):